Mortality and Its Predictors among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Systematic Review.

IF 1.1 Q4 INFECTIOUS DISEASES AIDS Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-10-30 DOI:10.1155/2017/5415298
Mohammed Biset Ayalew
{"title":"Mortality and Its Predictors among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Systematic Review.","authors":"Mohammed Biset Ayalew","doi":"10.1155/2017/5415298","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Even though the benefit of antiretroviral therapy (ART) is well established, there is a regional variation in the extent of its benefit. The aim of this review is to highlight mortality and its predictors in Ethiopian adult HIV patients who were on ART.</p><p><strong>Methods: </strong>Relevant articles were searched on PubMed and Google Scholar databases. The search terms used in different combinations were predictor/determinant/factors, mortality/death/survival, HIV, ART/HAART, and Ethiopia.</p><p><strong>Result: </strong>5-40.8% of the patients died during the follow-up period. More than half (50-68.8%) of the deaths occurred within 6 months of initiating ART. Advanced stage disease (stage III and stage IV), nonworking functional status (bedridden and ambulatory), low baseline CD4 count, low baseline hemoglobin level, TB coinfection, lower baseline weight, and poor treatment adherence were commonly identified as predictors of death in HIV patients.</p><p><strong>Conclusion: </strong>5-40.8% of HIV patients in Ethiopia die in 2-5 years of initiating antiretroviral treatment. Most of the deaths in HIV patients occur early in the course of treatment. Special emphasis should be given for patients with advanced stage disease, nonworking functional status, low baseline CD4 count, low baseline hemoglobin level, TB coinfection, lower baseline weight, and poor treatment adherence.</p>","PeriodicalId":46303,"journal":{"name":"AIDS Research and Treatment","volume":"2017 ","pages":"5415298"},"PeriodicalIF":1.1000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/5415298","citationCount":"53","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/5415298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/10/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 53

Abstract

Background: Even though the benefit of antiretroviral therapy (ART) is well established, there is a regional variation in the extent of its benefit. The aim of this review is to highlight mortality and its predictors in Ethiopian adult HIV patients who were on ART.

Methods: Relevant articles were searched on PubMed and Google Scholar databases. The search terms used in different combinations were predictor/determinant/factors, mortality/death/survival, HIV, ART/HAART, and Ethiopia.

Result: 5-40.8% of the patients died during the follow-up period. More than half (50-68.8%) of the deaths occurred within 6 months of initiating ART. Advanced stage disease (stage III and stage IV), nonworking functional status (bedridden and ambulatory), low baseline CD4 count, low baseline hemoglobin level, TB coinfection, lower baseline weight, and poor treatment adherence were commonly identified as predictors of death in HIV patients.

Conclusion: 5-40.8% of HIV patients in Ethiopia die in 2-5 years of initiating antiretroviral treatment. Most of the deaths in HIV patients occur early in the course of treatment. Special emphasis should be given for patients with advanced stage disease, nonworking functional status, low baseline CD4 count, low baseline hemoglobin level, TB coinfection, lower baseline weight, and poor treatment adherence.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
埃塞俄比亚接受抗逆转录病毒治疗的艾滋病毒感染者死亡率及其预测因素:一项系统综述
背景:尽管抗逆转录病毒治疗(ART)的益处已得到充分确认,但其益处程度存在地区差异。本综述的目的是强调接受抗逆转录病毒治疗的埃塞俄比亚成年艾滋病毒患者的死亡率及其预测因素。方法:在PubMed和Google Scholar数据库中检索相关文献。在不同组合中使用的搜索词是预测/决定/因素、死亡率/死亡/生存、HIV、ART/HAART和埃塞俄比亚。结果:5-40.8%的患者在随访期间死亡。一半以上(50-68.8%)的死亡发生在开始抗逆转录病毒治疗后的6个月内。晚期疾病(III期和IV期)、非工作功能状态(卧床和走动)、低基线CD4计数、低基线血红蛋白水平、结核病合并感染、较低的基线体重和较差的治疗依从性通常被认为是HIV患者死亡的预测因素。结论:埃塞俄比亚5-40.8%的艾滋病患者在开始抗逆转录病毒治疗的2-5年内死亡。大多数艾滋病毒患者的死亡发生在治疗过程的早期。应特别重视疾病晚期、功能状态不正常、基线CD4计数低、基线血红蛋白水平低、结核病合并感染、基线体重较低和治疗依从性差的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
AIDS Research and Treatment
AIDS Research and Treatment INFECTIOUS DISEASES-
CiteScore
3.10
自引率
0.00%
发文量
13
审稿时长
18 weeks
期刊介绍: AIDS Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis of disease to translational and clinical research. In addition, articles relating to prevention, education, and behavior change will be considered
期刊最新文献
Overweight and Obesity Among People Living With HIV on Dolutegravir- and Efavirenz-Based Therapies: A Comparative Cross-Sectional Study. Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa. Weight and Lipid Levels in People Living With HIV and Initiating a Dolutegravir-Based Regimen in a Resource Limited Setting: A Prospective Study. A Characterization of Women Living with HIV in Belgium. Relationship between Stress and Neuroimmunological Responses and Health Literacy in Newly Diagnosed HIV-Infected Patients: An Exploratory Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1